公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2004 | Dual and opposing roles of ERK in regulating G1 and S-G 2/M delays in A549 cells caused by hyperoxia | JEN-CHUNG KO ; Wang Y.-T.; Yang J.-L. | Experimental Cell Research | 18 | 14 | |
2020 | Effect of β-Blocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs | CHIA-HAO CHANG ; Lee C.-H.; JEN-CHUNG KO ; LIH-YU CHANG ; Lee M.-C.; Zhang J.-F.; JANN-YUAN WANG ; JIN-YUAN SHIH ; CHONG-JEN YU | Frontiers in Oncology | 9 | 8 | |
2021 | Efficacy and safety of cone-beam computed tomography-derived augmented fluoroscopy combined with endobronchial ultrasound in peripheral pulmonary lesions | KAI-LUN YU ; SHUN-MAO YANG ; Ko, Huan-Jang; Tsai, Hui-Yu; JEN-CHUNG KO ; CHING-KAI LIN ; CHAO-CHI HO ; JIN-YUAN SHIH | Respiration | 19 | 18 | |
2010 | Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2 | JEN-CHUNG KO ; Su Y.-J.; Lin S.-T.; Jhan J.-Y.; Ciou S.-C.; Cheng C.-M.; Chiu Y.-F.; Kuo Y.-H.; Tsai M.-S.; Lin Y.-W. | Lung Cancer | 48 | 43 | |
2009 | Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation | Chen R.-S.; Jhan J.-Y.; Su Y.-J.; Lee W.-T.; Cheng C.-M.; Ciou S.-C.; Lin S.-T.; Chuang S.-M.; JEN-CHUNG KO ; Lin Y.-W. | Experimental Cell Research | 28 | 26 | |
2021 | Exploring volatile organic compounds in breath for high-accuracy prediction of lung cancer | PING-HSIEN TSOU ; Lin Z.-L.; Pan Y.-C.; Yang H.-C.; CHIEN-JEN CHANG ; SHENG-KAI LIANG ; Wen Y.-F.; Chang C.-H.; LIH-YU CHANG ; KAI-LUN YU ; CHIA-JUNG LIU ; LI-TA KENG ; MENG-RUI LEE ; JEN-CHUNG KO ; Huang G.-H.; Li Y.-K. | Cancers | 33 | 19 | |
2019 | Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study | Wei Y.-F.; Huang W.-T.; Liu T.-C.; Shieh J.-M.; Chian C.-F.; Wu M.-F.; Chang C.-C.; Lin C.-H.; JEN-CHUNG KO ; Lin C.-M.; Hsia T.-C. | Journal of Cancer | 7 | 6 | |
2015 | Factors associated with subsequent nontuberculous mycobacterial lung disease in patients with a single sputum isolate on initial examination | MENG-RUI LEE ; Yang C.-Y.; CHIN-CHUNG SHU ; CHING-KAI LIN ; Wen Y.-F.; Lee S.-W.; JEN-CHUNG KO ; JANN-YUAN WANG ; LI-NA LEE ; CHONG-JEN YU | Clinical Microbiology and Infection | 22 | 18 | |
2021 | Functional Status After Pulmonary Rehabilitation as a Predictor of Weaning Success and Survival in Patients Requiring Prolonged Mechanical Ventilation | LI-TA KENG ; SHENG-KAI LIANG ; Tseng C.-P.; Wen Y.-F.; PING-HSIEN TSOU ; CHIA-HAO CHANG ; LIH-YU CHANG ; KAI-LUN YU ; MENG-RUI LEE ; JEN-CHUNG KO | Frontiers in Medicine | 2 | 1 | |
2017 | Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan | LIH-YU CHANG ; Lee C.-H.; JEN-CHANG KO ; Chang L.-Y.; Lee M.-C.; JANN-YUAN WANG ; CHONG-JEN YU | Cancer Medicine | 8 | 7 | |
2022 | Heat shock protein 90 inhibitor 17-AAG down-regulates thymidine phosphorylase expression and potentiates the cytotoxic effect of tamoxifen and erlotinib in human lung squamous carcinoma cells | JEN-CHUNG KO ; Chen, Jyh-Cheng; Hsieh, Jou-Min; Tseng, Pei-Yu; Chiang, Chen-Shan; Liu, Li-Ling; Chien, Chin-Cheng; Huang, I-Hsiang; Chang, Qiao-Zhen; Mu, Bo-Cheng; Lin, Yun-Wei | Biochemical pharmacology | 3 | 2 | |
2012 | HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells | JEN-CHANG KO ; Chen H.-J.; Huang Y.-C.; Tseng S.-C.; Weng S.-H.; Wo T.-Y.; Huang Y.-J.; Chiu H.-C.; Tsai M.-S.; Chiou R.Y.Y.; Lin Y.-W. | Regulatory Toxicology and Pharmacology | 17 | 18 | |
2023 | Incidence of and Risk Factors for Acute Kidney Injury During Antituberculosis Treatment: A Prospective Cohort Study and Literature Review | CHIA-HAO CHANG ; LIH-YU CHANG ; JEN-CHUNG KO ; Wen, Yueh-Feng; CHIEN-JEN CHANG ; LI-TA KENG ; PING-HSIEN TSOU ; KAI-LUN YU ; JANN-YUAN WANG ; CHONG-JEN YU | Infectious diseases and therapy | 2 | 1 | |
2013 | Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells | JEN-CHANG KO ; Chiu H.-C.; Wo T.-Y.; Huang Y.-J.; Tseng S.-C.; Huang Y.-C.; Chen H.-J.; Syu J.-J.; Chen C.-Y.; Jian Y.-T.; Jian Y.-J.; Lin Y.-W. | Lung Cancer | 22 | 20 | |
2019 | Inhibition of thymidine phosphorylase expression by Hsp90 inhibitor potentiates the cytotoxic effect of salinomycin in human non-small-cell lung cancer cells | JEN-CHUNG KO ; Chen J.-C.; Chen T.-Y.; Yen T.-C.; Ma P.-F.; Lin Y.-C.; Wu C.-H.; Peng Y.-S.; Zheng H.-Y.; Lin Y.-W. | Toxicology | 4 | 3 | |
2008 | Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, Iressa R) and chemotherapeutic agents in human lung cancer cells | JEN-CHUNG KO ; Ciou S.-C.; Cheng C.-M.; Wang L.-H.; Hong J.-H.; Jheng M.-Y.; Ling S.-T.; Lin Y.-W. | Carcinogenesis | 55 | 54 | |
1992 | Lobar bronchioloalveolar carcinoma: an ultrasound study. | JEN-CHUNG KO ; PAN-CHYR YANG ; KWEN-TAY LUH ; Kuo S.H.; Chang D.B.; CHONG-JEN YU | Journal of the Formosan Medical Association = Taiwan yi zhi | 3 | 0 | |
2013 | Metformin induces cytotoxicity by down-regulating thymidine phosphorylase and excision repair cross-complementation 1 expression in non-small cell lung cancer cells | JEN-CHANG KO ; Huang Y.-C.; Chen H.-J.; Tseng S.-C.; Chiu H.-C.; Wo T.-Y.; Huang Y.-J.; Weng S.-H.; Chiou R.Y.Y.; Lin Y.-W. | Basic and Clinical Pharmacology and Toxicology | 17 | 16 | |
2015 | Minocycline enhances mitomycin C-induced cytotoxicity through down-regulating ERK1/2-mediated Rad51 expression in human non-small cell lung cancer cells | JEN-CHANG KO ; Wang T.-J.; Chang P.-Y.; Syu J.-J.; Chen J.-C.; Chen C.-Y.; Jian Y.-T.; Jian Y.-J.; Zheng H.-Y.; Chen W.-C.; Lin Y.-W. | Biochemical Pharmacology | 7 | 5 | |
2011 | Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine | JEN-CHUNG KO ; Tsai M.-S.; Kuo Y.-H.; Chiu Y.-F.; Weng S.-H.; Su Y.-C.; Lin Y.-W. | Biochemical Pharmacology | 29 | 25 | |